CMS Unconvinced On PET Scans For Bone Metastasis; CED Data Not Enough
This article was originally published in The Gray Sheet
Executive Summary
While National Oncologic PET Registry data has been effective in persuading CMS to remove evidence-development restrictions from positron emission tomography coverage policies in the past, NOPR data was not enough to support coverage of PET scans to identify bone metastasis in a Dec. 15 national coverage determination.
You may also be interested in...
Bending To Overwhelming Feedback, CMS Softens Stance On PET For Solid Tumors
In a final decision memo released June 11, the Medicare agency provides national coverage for three post-cancer-treatment PET scans. The original coverage proposal would have allowed only one.
Imaging Registry Begins: Coverage-With-Evidence Policy Gets A Second Wind
The May 8 commencement of a nationwide positron emission tomography imaging registry is an important step forward for CMS' fledgling coverage-with-evidence-development (CED) policy, not to mention for expanded use of PET scans
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.